CB1 receptors were 20% elevated in the prefrontal cortex of people who died with major depression

In postmortem prefrontal cortex (BA9) of 23 MDD subjects versus 19 controls, CB1 receptor density was increased by 20% (p=0.02). This upregulation was significant in antidepressant-treated subjects (+23%, p=0.02) but not in antidepressant-free subjects (+14%, p=0.34). CB2 receptor density was unchanged. mTOR activity was increased by 29% (p=0.002) in both antidepressant-treated and untreated MDD subjects. JNK1/2 activity and neuroplastic proteins (PSD-95, Arc, spinophilin) were unchanged.

Immunoblotting quantification of CB1, CB2, mTOR, JNK1/2, and neuroplastic proteins in postmortem prefrontal cortex from 23 MDD subjects (suicide victims) and 19 matched controls.

This provides direct human brain evidence that the endocannabinoid system is altered in depression. The CB1 upregulation may represent a compensatory response to reduced endocannabinoid tone, offering a biological rationale for cannabinoid-based antidepressant strategies.

CB1 upregulation in depression could reflect the brain compensating for insufficient endocannabinoid signaling. If endocannabinoid deficiency contributes to depression, therapies that boost endocannabinoid levels (like FAAH inhibitors) might address this directly.

Postmortem tissue (cannot establish causation or temporal sequence); all MDD subjects were suicide victims (may not represent all depression); antidepressant treatment confounds interpretation; relatively small sample; cannot determine if CB1 changes cause or result from depression.